

NEW DATA PUBLISHED ON APAS® TECHNOLOGY – PRESENTS LBT AS LEADERS IN DIGITAL MICROBIOLOGY

APAS® Independence reduces microbiologist hands-on time to report Urine cultures

Adelaide, Australia, 31 August 2022: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce two new high impact peer reviewed publications featuring the APAS® technology presented in premier microbiology journals.

Key Points:

- **US clinical data demonstrates efficiency gains for laboratories using APAS® Independence**
 - Results released faster using APAS® compared to standard process
 - APAS® auto-validates and releases results without user intervention
 - Quick adoption into routine use, a major advantage compared to total lab automation
- **Microbiology 2.0: LBT presented as thought leaders in digital microbiology using artificial intelligence**

APAS® Independence reduces Urine culture plate reading times

The results, presented in the high impact journal, Microbiology Spectrum, demonstrated the APAS® Independence was able to significantly decrease manual Urine culture processing times, while maintaining consistent results with the standard of care. The report is the first study to independently prove with statistical rigour the positive impact to laboratory processing times as a result of implementing the APAS® Independence and will serve as a key reference point for future customers considering adoption of the technology. The study was completed by the University of California San Diego (UCSD) over a 4-month period.

UCSD Director of Microbiology & Associate professor of Pathology, Dr David T. Pride said:

“A major benefit of the APAS® system is its ability to expedite urine culture interpretation while fitting into a standard laboratory workflow, rather than requiring an overhaul of laboratory workflows.”

For access to the article on LBT’s website, please click [here](#).

LBT present Microbiology 2.0 - Considerations for implementation of AI for routine culture plate reading

LBT have had a paper published by Frontiers in Microbiology, providing “*behind the scenes*” insight into the challenges and considerations of developing artificial intelligent technologies for clinical microbiology. The paper is the first such peer-reviewed publication of its kind and positions LBT as thought-leaders in digital microbiology.

LBT Scientific Director, Dr Steven Giglio said:

“There is growing acceptance and adoption of digital microbiology in the industry. LBT have been at the forefront of this transition, and high impact articles in leading scientific literature, are critical to establishing credibility and trust with our customers. As the first peer-reviewed paper of its kind, this paper will become a key reference point as the industry advances.”

For access to the article on LBT’s website, please click [here](#).

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Channel partners for the sale and distribution of the APAS® Independence are in place for the United States (Thermo Fisher Scientific, Inc; Exclusive Distributor) and selected countries in Europe (Beckman Coulter, Inc; Marketing Agent).

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@btinnovations.com